Equities research analysts expect that Uniqure NV (NASDAQ:QURE) will announce $2.29 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Uniqure’s earnings, with the highest sales estimate coming in at $2.55 million and the lowest estimate coming in at $2.00 million. Uniqure posted sales of $3.15 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 27.3%. The company is scheduled to issue its next earnings results on Tuesday, November 5th.
On average, analysts expect that Uniqure will report full-year sales of $7.73 million for the current year, with estimates ranging from $5.00 million to $9.63 million. For the next year, analysts anticipate that the business will post sales of $10.61 million, with estimates ranging from $5.00 million to $25.40 million. Zacks’ sales averages are an average based on a survey of research firms that cover Uniqure.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.08). Uniqure had a negative return on equity of 61.67% and a negative net margin of 1,232.30%. The company had revenue of $2.47 million for the quarter, compared to the consensus estimate of $1.53 million.
QURE traded up $1.89 on Monday, hitting $42.70. 657,275 shares of the company were exchanged, compared to its average volume of 603,754. The firm has a fifty day simple moving average of $48.86 and a two-hundred day simple moving average of $60.50. The company has a debt-to-equity ratio of 0.51, a quick ratio of 8.07 and a current ratio of 8.07. Uniqure has a 12 month low of $21.98 and a 12 month high of $82.49. The stock has a market capitalization of $1.62 billion, a PE ratio of -18.25 and a beta of 0.84.
In other news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $71.45, for a total value of $571,600.00. Following the completion of the transaction, the chief executive officer now owns 404,839 shares in the company, valued at approximately $28,925,746.55. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Robert Gut sold 4,769 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $47.16, for a total value of $224,906.04. Following the completion of the transaction, the insider now owns 35,378 shares of the company’s stock, valued at approximately $1,668,426.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,229 shares of company stock valued at $2,204,241. 2.91% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Parametric Portfolio Associates LLC raised its stake in Uniqure by 8.4% during the second quarter. Parametric Portfolio Associates LLC now owns 4,835 shares of the biotechnology company’s stock valued at $378,000 after buying an additional 376 shares during the last quarter. US Bancorp DE raised its stake in Uniqure by 275.5% during the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 427 shares during the last quarter. Griffin Asset Management Inc. purchased a new position in Uniqure during the second quarter valued at $39,000. Royal Bank of Canada raised its stake in Uniqure by 9.7% during the second quarter. Royal Bank of Canada now owns 6,075 shares of the biotechnology company’s stock valued at $474,000 after buying an additional 536 shares during the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new position in Uniqure during the second quarter valued at $78,000. Institutional investors own 69.89% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Read More: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.